UNLABELLED: Familial Mediterranean fever (FMF) is an autoinflammatory disease and belongs to the heterogeneous group of hereditary recurrent fever syndromes (HRFs). AIMS: The aims of the study were to determine the incidence of FMF in Germany and to describe the spectrum of pyrin mutations and the clinical characteristics in children. A prospective surveillance of children with HRF including FMF was conducted in Germany during a time period of 3 years by the German paediatric surveillance unit for rare paediatric diseases (ESPED). Monthly inquiries were sent to 370 children's hospitals (Clinic-ESPED, n1) and to 23 laboratories (Laboratory-ESPED, n2). Inclusion criteria were children ≤ 16 years of age, disease-associated pyrin mutations, and more than three self-limiting episodes of fever >38.5 °C with increased inflammation markers. In n1, 122 patients with FMF and 225 pyrin mutations were identified. Ninety-two of 122 (75 %) children were of Turkish origin. The minimum incidence of FMF was estimated to be 3 (95 % CI: 2.48-3.54) per 10(6) person-years in the whole children population and 55 (95 % CI: 46-66) per 10(6) person-years in Turkish children living in Germany. N1 U n2 amounted to 593 asymptomatic and symptomatic carriers of 895 mutations (overlap of 73 cases with 134 mutations). p.Met694Val (45 %), p.Met680Ile (14 %), p.Val726Ala (12 %), and p.Glu148Gln (11.5 %) were the most common pyrin mutations. CONCLUSIONS: Despite FMF being the most frequent of the HRFs, its incidence in Germany is low. Twenty-five to 50 FMF patients ≤ 16 years are newly diagnosed per year. The disease is most commonly observed in individuals of Turkish ancestry.
UNLABELLED: Familial Mediterranean fever (FMF) is an autoinflammatory disease and belongs to the heterogeneous group of hereditary recurrent fever syndromes (HRFs). AIMS: The aims of the study were to determine the incidence of FMF in Germany and to describe the spectrum of pyrin mutations and the clinical characteristics in children. A prospective surveillance of children with HRF including FMF was conducted in Germany during a time period of 3 years by the German paediatric surveillance unit for rare paediatric diseases (ESPED). Monthly inquiries were sent to 370 children's hospitals (Clinic-ESPED, n1) and to 23 laboratories (Laboratory-ESPED, n2). Inclusion criteria were children ≤ 16 years of age, disease-associated pyrin mutations, and more than three self-limiting episodes of fever >38.5 °C with increased inflammation markers. In n1, 122 patients with FMF and 225 pyrin mutations were identified. Ninety-two of 122 (75 %) children were of Turkish origin. The minimum incidence of FMF was estimated to be 3 (95 % CI: 2.48-3.54) per 10(6) person-years in the whole children population and 55 (95 % CI: 46-66) per 10(6) person-years in Turkish children living in Germany. N1 U n2 amounted to 593 asymptomatic and symptomatic carriers of 895 mutations (overlap of 73 cases with 134 mutations). p.Met694Val (45 %), p.Met680Ile (14 %), p.Val726Ala (12 %), and p.Glu148Gln (11.5 %) were the most common pyrin mutations. CONCLUSIONS: Despite FMF being the most frequent of the HRFs, its incidence in Germany is low. Twenty-five to 50 FMFpatients ≤ 16 years are newly diagnosed per year. The disease is most commonly observed in individuals of Turkish ancestry.
Authors: Jae Jin Chae; Young-Hun Cho; Geun-Shik Lee; Jun Cheng; P Paul Liu; Lionel Feigenbaum; Stephen I Katz; Daniel L Kastner Journal: Immunity Date: 2011-05-19 Impact factor: 31.745
Authors: T Kümpfel; L-A Gerdes; T Wacker; A Blaschek; J Havla; M Krumbholz; W Pöllmann; W Feneberg; R Hohlfeld; P Lohse Journal: Mult Scler Date: 2012-02-15 Impact factor: 6.312
Authors: Elke Lainka; Maria Bielak; Volker Hilger; Oliver Basu; Ulrich Neudorf; Helmut Wittkowski; Dirk Holzinger; Johannes Roth; Tim Niehues; Dirk Foell Journal: Rheumatology (Oxford) Date: 2011-01 Impact factor: 7.580
Authors: Isabelle Touitou; Suzanne Lesage; Michael McDermott; Laurence Cuisset; Hal Hoffman; Catherine Dode; Nitza Shoham; Ebun Aganna; Jean-Pierre Hugot; Carol Wise; Hans Waterham; Denis Pugnere; Jacques Demaille; Cyril Sarrauste de Menthiere Journal: Hum Mutat Date: 2004-09 Impact factor: 4.878
Authors: A Giese; A Ornek; M Kurucay; L Kilic; S N Şendur; A Münker; C Puchstein; E Lainka; H Wittkowski; B F Henning Journal: Schmerz Date: 2013-12 Impact factor: 1.107
Authors: Mati Chuamanochan; Karsten Weller; Eugen Feist; Tilmann Kallinich; Marcus Maurer; Jasmin Kümmerle-Deschner; Karoline Krause Journal: World Allergy Organ J Date: 2019-03-14 Impact factor: 4.084
Authors: Annalisa Marcuzzi; Elisa Piscianz; Giulio Kleiner; Alberto Tommasini; Giovanni Maria Severini; Lorenzo Monasta; Sergio Crovella Journal: Biomed Res Int Date: 2013-01-01 Impact factor: 3.411
Authors: Arnd Giese; Ahmet Ornek; Mustafa Kurucay; Kaffer Kara; Helmut Wittkowski; Faekah Gohar; Bjoern A Menge; Wolfgang E Schmidt; Christoph Zeidler Journal: Int J Med Sci Date: 2014-08-21 Impact factor: 3.738